Q3 INTERIM REPORT July-Sept 2024

Mentice has received a €1,062,750 EUR order for simulation solutions from a top 20 global MedTech company

Mentice to present the company's Q2-2024 Interim Report

Tuesday, July 9, 2024

Mentice AB (STO: MNTC) announces that the company will present its interim report via webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Ulrika Drotz.

The presentation of the Q2 Interim Report for the period April – June 2024 will be held on July 23 at 10:00 CEST. The live broadcast is followed by a Q&A moderated by Redeye’s analyst Christian Binder. For more information on how to join, please visit https://investor.mentice.com/.

The presentation will be held in English. Participants are advised to join at least a few minutes in advance.

About Mentice
Mentice (STO: MNTC) is the world leader in proficiency based simulation solutions for image guided interventional therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at: www.mentice.com

Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC
Certified Adviser| FNCA Sweden AB